文献速递消化、代谢与肾脏急症重症综合管理与镇静镇痛

重症患者高血糖的连续葡萄糖监测:一项随机对照试验

Continuous Glucose Monitoring for Hyperglycemia in Critically Ill Patients: A Randomized Controlled Trial.
PubMed 文献 · Chest · 2025-02-15
一句话结论在重症高血糖患者中,连续葡萄糖监测(CGM)与标准血糖监测相比,目标血糖范围内时间百分比无统计学显著差异(60.5% vs 61.4%,P=0.9)。

本研究为 investigator-initiated、单中心、平行组、开放标签随机对照试验,纳入内科或外科 ICU 中合并糖尿病或高血糖且接受胰岛素治疗的成人患者 85 例,随机分为 CGM 组(43 例)和标准治疗组(42 例)。主要终点为目标血糖范围(70–180 mg/dL,即 3.9–10 mmol/L)内时间百分比,CGM 组为 60.5%±30.5%,标准治疗组为 61.4%±28.3%,均差 -0.9%(95%CI -13.6 至 11.8;P=0.9),无统计学显著差异。除患者满意度外,两组次要和探索性终点均无统计学显著差异。研究结论不支持 CGM 作为 ICU 常规血糖监测的优越方法。

要点

  • 目标血糖范围 70–180 mg/dL(3.9–10 mmol/L)内时间百分比:CGM 组 60.5%±30.5% vs 标准治疗组 61.4%±28.3%,均差 -0.9%(95%CI -13.6 至 11.8;P=0.9),无统计学显著差异。
  • 除患者满意度外,两组次要和探索性终点均无统计学显著差异。
  • 研究纳入内科或外科 ICU 中合并糖尿病或高血糖且接受胰岛素治疗的成人患者,共 85 例(CGM 组 43 例,标准治疗组 42 例)。
  • 研究结论不支持 CGM 作为 ICU 常规血糖监测的优越方法。

适用人群与场景

  • 纳入标准:收入内科或外科 ICU 的成人患者,合并糖尿病或高血糖,且正在接受胰岛素治疗。

诊断标准与关键阈值

  • 目标血糖范围定义为 70–180 mg/dL(3.9–10 mmol/L)。

研究设计与关键结果

  • 研究类型:investigator-initiated、单中心、平行组、开放标签随机对照试验;样本量 85 例,CGM 组 43 例,标准治疗组 42 例。
  • 主要终点:目标血糖范围(70–180 mg/dL,即 3.9–10 mmol/L)内时间百分比,CGM 组 60.5%±30.5% vs 标准治疗组 61.4%±28.3%,均差 -0.9%(95%CI -13.6 至 11.8;P=0.9),无统计学显著差异。
  • 次要和探索性终点:除患者满意度外,两组间均无统计学显著差异。

证据类型、等级与局限

  • 证据类型:随机对照试验(RCT)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 研究结论不支持 CGM 作为 ICU 常规血糖监测的优越方法。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Continuous glucose monitors (CGMs) could potentially improve management of hyperglycemia compared with standard point-of-care glucose monitoring for critically ill patients. However, there is limited evidence to support routine use of CGMs in the ICU.

RESEARCH QUESTION: In critically ill patients with hyperglycemia, do CGMs improve time within target glucose range compared with standard of care?

STUDY DESIGN AND METHODS: This was an investigator-initiated, single-center, parallel-group, open-label, randomized controlled trial. Adult patients admitted to a medical or surgical ICU who had diabetes mellitus or hyperglycemia and were treated with insulin were eligible for enrollment. Participants were randomly assigned to have glucose monitoring performed with a CGM (intervention group) or standard of care (control group). Groups were compared for glycemic control and other relevant outcomes. The primary outcome for the study was percentage of time within the normoglycemic range, defined as 70 to 180 mg/dL (3.9-10 mmol/L).

RESULTS: Eighty-five participants were enrolled and randomized to study groups, with 43 participants in the intervention (CGM) group and 42 patients in the control (standard of care) group. For the primary outcome, there was no statistically significant difference between the intervention group (mean ± SD, 60.5% ± 30.5%) and the control group (mean ± SD, 61.4% ± 28.3%) in time within the goal glucose range (mean difference, -0.9%; 95% CI, -13.6 to 11.8; P = .9). Except for patient satisfaction, there were no statistically significant differences between groups for secondary and exploratory outcomes.

INTERPRETATION: The results of this study do not support CGMs as a superior method for routine glucose monitoring in the ICU compared with standard of care.

CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT05442853; URL: www.

CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Franck AJ, Hendrickson AL, Telford ED, et al. Continuous Glucose Monitoring for Hyperglycemia in Critically Ill Patients: A Randomized Controlled Trial. Chest. 2025. PMID: 39956190. doi:10.1016/j.chest.2025.02.006

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。